Biogen Idec’s 2003 Press Releases

by

Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.

2003 Back to main index

12/7/2003

Initial Data From Phase III ECOG 4494 Study of Rituxan as Front-Line and Maintenance Therapy in Aggressive Non-Hodgin’s Lymphoma (NHL) Presented at ASH

12/7/2003

Initial Results of a New Study of Rituxan Plus CVP Chemotherapy Demonstrate Prolonged Time to Treatment Failure as Front-Line Therapy for Patinets with Indolent Non-Hodgins’s Lymphoma

12/7/2003

Initial Results of a Randomized Phase II Study Suggest That Rituxan Maintance Therapy Prolongs Remission in Indolent NHL

12/7/2003

Zevalin® (Ibritumomab tiuxetan) Therapeutic Regimen Produces Long-Term Durable Remissions in Patients with Non-Hodgkin’s Lymphoma

11/13/2003

Eastern Cooperative Oncology Group (Ecog) Phase III Trial Of Rituxan Maintenance Therapy In Indolent Non-Hodgkin’s Lymphoma Reaches Pre-Specified Efficacy Endpoint Early

11/12/2003

Biogen and IDEC Pharmaceuticals Complete Merger to Create New Biotechnology Industry Leader

2003 Back to main index